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Abstract 
 
Objectives: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in 
hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical 
trial. 
 
Subjects/patients and Methods: Patients in the West of Scotland Cancer Network (WoSCAN) 
with newly diagnosed mPC were identified from the regional multidisciplinary team (MDT) 
meetings and their treatment details were collected from electronic patient records. The 
rate of febrile neutropenia, hospitalisations, time to progression and overall survival were 
compared between those patients who received docetaxel and androgen deprivation 
therapy (ADT), or ADT alone using survival analysis. 
 
Results: Out of 270 eligible patients, 103 received docetaxel (38.1%). 35 patients (34%) were 
hospitalised and there were 17 episodes of febrile neutropenia (16.5%). Two patients (1.9%) 
died within 30 days of chemotherapy. Patients who received ADT alone had an increased 
risk of progression (HR 2.03, 95% CI (1.27, 3.25), log-rank test, p= 0.002) and had an 
increased risk of death (HR 5.88, 95% CI 2.52, 13.72, log-rank p=0.001) compared to the 
docetaxel group. The risk of febrile neutropenia was nine times greater if chemotherapy 
was started within three weeks of ADT initiation (95% CI (1.22,77.72) p= 0.032).  
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Conclusion: Docetaxel chemotherapy in hormone-naïve mPC has significant toxicities, but 
has a similar effect on time to progression and overall survival as seen in randomised trials. 
Chemotherapy should be started 3 weeks or more after androgen deprivation. 
Keywords: Docetaxel, Hormone-naïve, Metastatic, Prostate Cancer, Real World 
 
 
Introduction 
 
Across the UK, approximately 11,300 men died from prostate cancer in 2014, making it the 
second most common cause of cancer death in males. The majority of these deaths are in 
men over the age of 80, and those diagnosed with metastatic disease have a five-year 
survival of only 30% [1]. Most patients with metastatic prostate cancer (mPC) respond 
initially to androgen suppression but invariably become resistant to hormone manipulation. 
For patients with hormone-resistant mPC, docetaxel has been the standard of care for over 
a decade, with a median improvement in overall survival of 2.9 months when compared to 
mitoxantrone [2],[3].  
 
However, recent clinical trials showed a larger overall survival gain when docetaxel is given 
in the hormone-naïve setting. Two large randomised controlled trials, STAMPEDE [4] and 
CHAARTED [5], both showed a significant benefit in overall survival when docetaxel 
chemotherapy was added to standard androgen deprivation therapy (ADT) near the time of 
initiation. The median survival gain reported in these studies was 10 and 13.6 months 
respectively, and in a subgroup analysis of the STAMPEDE data, the effect was larger in 
patients with metastatic (M1) disease. Although an earlier French study, GETUG-AFU 15 [6], 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
did not show a significant benefit, meta-analysis of these three trials confirms a clear 
survival gain for patients with mPC [7]. In the STAMPEDE study, the rate of grade 3 or above 
adverse events in the first year was 51% in the chemotherapy and ADT arm compared to 
31% in the standard of care arm. The toxicity in the chemotherapy arms became equivalent 
to the standard of care (SOC) arm after the first year. There were 8 chemotherapy related 
deaths in the docetaxel containing arms of STAMPEDE (0.67%). 
 
The West of Scotland Cancer Network (WoSCAN) establishes protocols and pathways for the 
care of all National Health Service (NHS) patients within a catchment area of 2.8 million 
people. WoSCAN recruited actively to the STAMPEDE trial, and was able to change practice 
within days of the release of the STAMPEDE results. In June 2015 the WoSCAN clinical 
management guideline for newly-diagnosed mPC changed with the addition of docetaxel 
chemotherapy to ADT in hormone-naïve mPC patients fit enough to receive it. 
 
The data presented here analyse the safety and efficacy of docetaxel chemotherapy in 
hormone-naïve prostate cancer in the first year of use outside of a clinical trial. 
 
Subjects/patients and methods 
 
Patients and Data collection 
 
All patients discussed in the four multi-disciplinary team (MDT) meetings within WoSCAN 
(Lanarkshire, Ayrshire and Arran, Pan-Glasgow and Forth Valley) between 6th June 2015 and 
2nd June 2016, who were newly diagnosed with mPC were included in this analysis. The MDT 
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confirmed the diagnosis and staging of every new prostate cancer on the basis of either 
biopsy (of either primary or metastases) and/or PSA greater than 100ng/ml with abnormal 
digital rectal examination (DRE). In patients who were unfit for biopsy and had a PSA of less 
than 100ng/ml, the diagnosis was made clinically by the MDT. Metastatic disease was 
diagnosed on imaging (computed tomography (CT), magnetic resonance imaging (MRI) or 
isotope bone scan). Patients who had previous local treatment and developed subsequent 
metastases were excluded. The decision to commence docetaxel was made by the treating 
oncologist. Each health board approved the release of patient information for this study. 
 
Baseline patient characteristics were collected from electronic patient records including age, 
Gleason score (if available), peak pre-ADT PSA, pre-ADT haemoglobin, pre-ADT alkaline 
phosphatase (ALP), pre-biopsy neutrophil lymphocyte ratio (NLR), pre-biopsy haemoglobin, 
and performance status as measured by the referrer to the MDT or the treating oncologist. 
 
The following treatment characteristics were obtained from electronic patient records and 
from Chemocare (an online platform to prescribe chemotherapy): type of ADT, date ADT 
commenced, date of starting chemotherapy, number of cycles of chemotherapy, hospital 
admissions within 30 days of chemotherapy, dose reductions, delayed treatments, time to 
PSA nadir, time to biochemical progression, neutropenic events and date of death. Time to 
PSA nadir and to biochemical progression were measured from the date of commencing 
ADT. Biochemical progression was deemed to have occurred if the PSA value had increased 
by 50% above nadir value, or, if the nadir value was less than 4ng/ml, the greater of either a 
50% rise from nadir or a PSA above 4ng/ml. Primary treatment failure was defined as a nadir 
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of greater than 50% of the initial PSA. Overall survival was measured from date of diagnosis 
to date of death, and the cut-off for data-analysis was 10th February 2017. 
 
The chemotherapy protocol consisted of docetaxel 75mg/m2 given on day 1 every 3 weeks 
plus prednisolone 5mg twice daily for a total of 6 cycles. Granulocyte-colony stimulating 
factors (G-CSF) were not routinely prescribed. Dose reductions and delays were at the 
treating oncologist’s discretion. The choice of ADT was as per regional protocols. 
 
Statistical analysis 
 
Baseline characteristics were compared using either Chi-squared or the Student’s t-test. 
Time to progression and overall survival was calculated using Kaplan-Meier plots and the 
log-rank test. Hazard ratios were obtained using Cox regression. Logistic regression was 
used to derive odds ratios for the risk of febrile neutropenia against time. All statistical 
analyses were performed using SPSS (Version 23, IBM). 
 
Results 
 
Baseline Characteristics 
 
We identified 280 patients who had newly diagnosed hormone-naïve mPC. Ten patients 
were excluded from the analysis (eight patient records were unavailable and two patients 
had chemotherapy in the hormone-resistant setting). The diagnosis was confirmed by either 
biopsy and/or PSA greater than 100ng/ml with abnormal DRE in 238 patients (88.2%). Of the 
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270 patients analysed, 103 (38.1%) had at least one cycle of docetaxel and 167 patients 
(61.8%) had ADT alone. Patients who had chemotherapy were significantly younger and the 
majority had a performance status of 0 or 1 (Table 1). Patients who had chemotherapy had 
a significantly higher median PSA. There were no significant differences between the two 
groups in terms of NLR, and pre-ADT ALP. 19.2% of patients treated with ADT alone were 
anaemic, compared to 6.7% in the docetaxel group (Chi-sq p=0.005). Performance status 
was unknown in 31.7% of patients who had ADT alone. There was no histological diagnosis 
in 85 patients (31.5%), the majority of which was in the ADT alone group, as this group had 
fewer biopsies than the chemotherapy group. 
 
 
 
Treatment characteristics 
 
The majority of patients in both groups received luteinizing hormone-releasing hormone  
(LHRH) agonists as ADT (Table 2). 83 patients (80.6%) who received docetaxel completed all 
six planned cycles. 68 patients (66.0%) had no dose modifications throughout the 
programme of chemotherapy, 30 patients (29.1%) needed one dose reduction and five 
patients (4.9%) required two dose reductions. 85 patients (82.5%) had no chemotherapy 
delays. 
 
Safety 
 
There were two deaths in the cohort of patients receiving docetaxel chemotherapy. One 
patient died from neutropenic sepsis after the sixth cycle of chemotherapy, and the other 
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was found dead at home after four cycles having declined admission to hospital whilst 
neutropenic 24 hours prior. 16 patients (15.5%) had four cycles of chemotherapy or less 
(Table 3). Infections (neutropenic, or non-neutropenic) accounted for 50% of early 
stoppages. 35 patients (34.0%) needed to be hospitalised during the course of 
chemotherapy, and for 17 patients (16.5%), this was due to febrile neutropenia. The risk of 
febrile neutropenia was on average nine times greater in those patients who started 
chemotherapy within 20 days of starting ADT compared to those who had started 
chemotherapy 80 days after commencing ADT (Table 4). 
 
Efficacy 
 
The time taken to reach PSA nadir was approximately 7 months for both patients who 
received chemotherapy and those who received ADT alone (HR 1.07, 95% CI 0.80, 1.42, log-
rank test p=0.665), Figure 1.1). Patients who received chemotherapy were more likely to 
have a nadir value of <0.2 compared to ADT alone (27 patients (26.2%) and 15 patients 
(8.9%) respectively, Chi-sq test, p=0.001). The chemotherapy group had a significantly 
longer time to biochemical progression, with the ADT alone group having a hazard ratio of 
2.03 for progression (95% CI (1.27, 3.25), log-rank test, p= 0.002, Figure 1.2). Patients who 
received ADT alone had a hazard ratio of 5.88 for death (95% CI 2.52, 13.72, log-rank 
p=0.001, Figure 1.3) compared to the chemotherapy group. Median overall survival has not 
yet been reached in either group. The minimum follow-up for the patients in this cohort 
from diagnosis was six months.  
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Discussion 
 
The data presented here are the largest series of real world information on the efficacy of 
docetaxel in men with newly diagnosed prostate cancer. Following the STAMPEDE data 
presented in ASCO 2015, it was adopted as the standard of care in the West of Scotland for 
those patients who were deemed fit for chemotherapy. These data show that less than 40% 
of all newly diagnosed mPC patients were commenced on chemotherapy. 80% of patients 
completed all six cycles. Over a third of patients were hospitalised during their treatment 
and the febrile neutropenia rate was 16.5%.  Interestingly, the risk of neutropenic sepsis 
falls dramatically with increasing time from the start of ADT. Median overall survival has not 
yet been reached, but the rate of biochemical progression is significantly less in the 
chemotherapy arm. 
 
The first randomised controlled trial that reported on the use of docetaxel in the hormone-
naïve setting was the GETUG-AFU 15 study, which compared ADT alone (n=193) against up 
to 9 cycles of docetaxel plus ADT (n=193). The median survival for docetaxel plus ADT was 
58.9 months, compared to 54.2 months with ADT alone (HR 1.01, 95% CI 0.75, 1.36, not 
significant). However, there was a significant improvement in biochemical progression free 
survival in favour of chemotherapy plus ADT (22.9 months against 12.9, p=0.005). Four 
patients (2.1%) died in the chemotherapy arm, two from infections while neutropenic (Table 
5). The trial management group amended the protocol to administer G-CSF with 
chemotherapy and after this change there were no more fatalities. The WOSCAN data 
demonstrate a similar mortality rate and this is a concern given that these patients would 
have expected to have experienced several years of disease control with ADT alone.  There 
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is some disparity between the rate of febrile neutropenia and mortality, which highlights 
that neutropenia is not the only contributory factor.  The rate of febrile neutropenia was 
similar to the experience from the Velindre cancer centre [8] which reported a rate of 20%. 
 
CHAARTED and STAMPEDE are two landmark studies that demonstrate a survival advantage 
with docetaxel in this setting. CHAARTED compared 6 cycles of docetaxel plus ADT (n=397) 
against ADT alone (n=393) and showed an overall survival benefit of 13.6 months (median 
OS 57.6 against 44.0 months respectively, HR for death 0.61 (95% CI, 0.47 – 0.80, p<0.001)). 
There was one chemotherapy related death in this trial and the use of G-CSF was as per 
investigator preference. The largest of these studies is STAMPEDE which included patients 
with metastatic disease and with high risk locally advanced cancer. STAMPEDE is a multi-
arm multi-stage trial which specified six cycles of chemotherapy plus ADT in Arm C (n=592), 
and with the addition of zoledronic acid in Arm E (n=593). This showed a 10 month overall 
survival benefit with ADT and chemotherapy (median OS 81 against 71 months in the ADT 
alone arm, HR 0.78, 95% CI 0.66-0.93, p=0.006). The addition of zoledronic acid had no 
effect on survival. The median time from commencing ADT to starting chemotherapy was 8 
weeks. 
 
We demonstrated a significantly increased risk of febrile neutropenia in patients who 
started docetaxel within 20 days of commencing ADT. The increased toxicity may be related 
to decreased docetaxel clearance in non-castrate men, independent of CYP3A4 activity, 
possibly due to alteration in the number and function of docetaxel transporters in the liver 
[9]. One putative mechanism of our finding is that the change in the hepatic transport 
proteins occurs over several weeks, and so patients who start sooner have a greater 
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exposure to docetaxel. Alternatively, patients with mPC are likely to have significant bone 
marrow infiltration, therefore less able to recover after cytotoxic chemotherapy. After 
several months of androgen suppression however, the disease burden in the bone marrow 
is less, and therefore is better able to maintain neutrophil counts when challenged with 
docetaxel. A third possible factor is the effect of androgen deprivation on neutrophil 
development and maturation. In mice studies, the androgen receptor is essential for 
neutrophil production [10], and it is possible that ADT in humans may have some effect on 
this process, although further evidence is required. 
 
The median time from commencing ADT to the start of chemotherapy was 1.2 months in 
CHAARTED and 2 months in STAMPEDE, which suggests that the efficacy of docetaxel is 
preserved if chemotherapy is started later. The relationship between time from ADT to 
chemotherapy and neutropenic sepsis requires further validation with the larger trial 
datasets. Given the high rate of febrile neutropenia, and its subsequent effect on treatment 
related deaths and early cessation, delaying the start of chemotherapy for at least 3 weeks 
after starting ADT should be considered. Guidelines on G-CSF use suggest using primary 
prophylaxis at a febrile neutropenia rate of greater than 20%, which is higher than 16.5% we 
observed [11]. However, the mPC population tend to be older and have more co-morbidities 
hence are less likely to cope with the physiological demands of neutropenic infections. 
Therefore G-CSF should be considered in those patients particularly at risk as a pragmatic 
measure.  
 
Approximately 40% of patients with treatment-naïve mPC proceeded to chemotherapy. This 
uptake is lower than expected, especially given a recent survey showing that 96% of uro-
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oncologists would prescribe docetaxel to patients with newly-diagnosed mPC [12]. Our data 
show that older patients and those with poor performance status were less likely to receive 
chemotherapy. It is possible that patients in these categories are less likely to be referred 
for oncological opinions leading to a false impression about the proportion of patients 
getting chemotherapy in routine oncological practice. Of note, our data included all patients 
with metastatic disease at diagnosis and not just those who presented to oncologists. 
Other possible reasons for this low uptake may be due to comorbidities that preclude 
chemotherapy (which were not accounted for in this study), or systemic issues regarding 
adopting new guidance through a cancer network.  
 
Although the STAMPEDE data included all patients with metastatic disease, pre-planned 
subgroup analysis of the CHAARTED trial suggested some uncertainty about the value of 
chemotherapy in patients with 'low volume' metastatic disease (defined as patients with 
less than four bone metastases, with none outside the vertebral bodies or pelvis and no 
visceral metastases). Our methodology did not permit us to explore the relationship 
between volume of disease and likelihood of receiving chemotherapy so, although regional 
guidelines recommend chemotherapy for all suitable patients with metastatic disease, it is 
possible that some of the lower than expected uptake was due to less use in patients with 
low volume disease. 
 
The patients who had docetaxel and ADT had a significantly lower risk of death, which is 
partially due to the patients in this group being younger and of better performance status. 
The duration of follow-up of this cohort of patients is too short to ascertain if the overall 
survival gain demonstrated in STAMPEDE and CHAARTED can be reproduced outside of a  
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clinical trial. However, our data regarding biochemical progression appears similar 
The limitations of this study are that the patients were drawn from a wide geographical 
area, therefore the recording of key characteristics such as performance status were 
incomplete in the ADT alone group. The reasons why patients did not have chemotherapy 
were difficult to ascertain as was the cause of death. Chemotherapy toxicities that did not 
result in a dose reduction were less reliably recorded. 
 
The strength of this study is that it comprehensively captures nearly all newly diagnosed 
patients over the first year of docetaxel use in clinical practice in WoSCAN, and provides 
robust data on the haematological toxicities and rate of hospitalisation and death. These 
data highlight the significant risks of chemotherapy in this population and the need to 
consider additional measures to reduce this. 
 
In conclusion, the safety and efficacy of first-line docetaxel in mPC are comparable to the 
clinical trials. There was a nine-fold increase in risk of febrile neutropenia if chemotherapy 
was started within 20 days of commencing ADT. The administration of G-CSF or delaying 
starting chemotherapy for at least three weeks after ADT should be considered to reduce 
this risk, and improve the safety of a proven life-extending intervention.  
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 Chemo + ADT (n=103) ADT alone (n=167)  
Median age (range)  68 (45-85) 81 (46-98) *p=0.001 
Age (%) <70 59 (57.3) 21 (12.6)  
 70 44 (42.7) 146 (87.4)  
Performance status (%) 0 60 (58.3) 9 (5.3) *p=0.001 
 1 40 (38.8) 38 (22.8)  
2 3 (2.9) 49 (29.3)  
3 0 18 (10.8)  
Unknown 0 53 (31.7)  
Sum Gleason Score (%) 6-7 23 (22.3) 20 (12.0)  
 8-10 65 (63.1) 56 (33.5)  
Unknown 15 (14.6) 91 (54.5)  
Median PSA (range)  218.5 (3-10353) 141 (1-5412) *p=0.006 
NLR <3 70 (68.0) 90 (53.9) p=0.454 
 >3 33 (32.0) 77 (46.1)  
Alkaline Phosphatase (%) <1.5 ULN 67 (65.0) 103 (61.7) p=0.508 
 1.5 ULN 35 (34.0) 64 (38.3)  
 Unknown 1 (1.0) 0  
Haemoglobin (%) <110 7 (6.8) 32 (19.2) *p=0.005 
 110 95 (92.2) 134 (80.2)  
 Unknown 1 (1.0) 1 (0.6)  
Table 1. Baseline characteristics 
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 Chemo + ADT (n=103) ADT alone (n=167) 
Type of ADT (%) LHRH agonist 71 (69.0) 96 (57.5) 
 Degarelix 26 (25.2) 62 (37.1) 
 Other 6 (5.8) 9 (5.4) 
No. of cycles (%) 1 5 (4.9) - 
 2 4 (3.9) - 
 3 4 (3.9) - 
 4 4 (3.9) - 
 5 4 (3.9) - 
 6 83 (80.6) - 
Table 2. Treatment characteristics 
 
 
 n (% of all docetaxel patients) 
Febrile neutropenia 4 (3.9) 
Non-neutropenic infections 4 (3.9) 
Neurotoxicity 2 (1.9) 
Not tolerated 1 (1.0) 
Diarrhoea 1 (1.0) 
ALT/AST elevation 1 (1.0) 
Interstitial pneumonitis 1 (1.0) 
Pulmonary embolism 1 (1.0) 
Death 1 (1.0) 
Table 3. Reasons for stopping chemotherapy at 4 cycles or less. ALT, Alanine transaminase. 
AST, Aspartate transaminase. 
 
 
Days from 
starting ADT to 
starting 
chemotherapy 
Neutropenic 
events 
Number of 
patients at 
risk 
Odds ratio of 
febrile 
neutropenia 
 
0-19 3  7  9.75 (1.22,77.72)  
p=0.032  
20-39 4 17 4 (0.65,24.77) 
p=0.136  
40-59 4 26 2.95 (0.52,16.76) 
p=0.221  
60-79 4 25 1.86 (0.28,12.16) 
p=0.519  
>79 2 28 1 (reference) - 
 
Table 4. Odds ratio of events of febrile neutropenia against time from starting ADT to 1st 
dose of docetaxel. 
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 STAMPEDE 
(Arms C+E, 
n=1185) 
CHAARTED 
(n=397) 
GETUG-AFU-
15 (n=192) 
WoSCAN 
(n=103) 
Treatment related 
deaths 
0.7% 0.2% 2.1% 1.9% 
Rate of febrile 
neutropenia 
14-15% 6% 4.1% 16.5% 
Grade 3-4 
toxicity/hospitalisation 
52% 16.6% 37.3% 
(approx) 
34% 
Table 5. Safety profile of ADT and docetaxel in WoSCAN compared to similar RCTs 
 
 
 
 
Figure 1.1 Kaplan-Meier plot for time to nadir. Median time to nadir was 6.5 months in the 
ADT alone group, compared to 7.8 months in the chemotherapy group. 
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Figure 1.2. Kaplan-Meier plot for time to progression. Median time to progression was 17.2 
months in the ADT alone group, and was not reached in the chemotherapy group. 
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Figure 1.3. Kaplan-Meier plot for overall survival. Neither group reached median survival.  
 
 
